Aclarion, Inc. Common Stock
ACONAclarion, Inc. (ACON) is a company focused on developing and commercializing innovative medical devices, particularly in the field of neurotechnology. They aim to improve target engagement and patient outcomes through advanced solutions that facilitate precise neurostimulation and neurofeedback.
Company News
Aclarion (NASDAQ: ACON) raised $10.4 million through common stock financing at $5.18 per share, extending its cash runway into 2028 with zero debt and $21.6 million in cash. The company plans to accelerate clinical trials for its Nociscan AI platform, expand access across MRI platforms, and pursue broader reimbursement. Despite strong 2025 adopti...
Aclarion, Inc. closed a $10.4 million common-stock financing at $5.18 per share, bringing cash reserves to $21.6 million with zero debt and extended runway into 2028. The company plans to advance its Nociscan clinical trial (CLARITY), expand MRI manufacturer access, and pursue broader payor coverage for its chronic low back pain diagnostic platfo...
Aclarion, a healthcare technology company, reported 69% year-over-year growth in Nociscan scan volumes for 2025, with Q4 showing 114% growth. The company maintains a debt-free balance sheet with $12.0 million in cash, providing runway into 2027. Aclarion is advancing its CLARITY clinical trial with plans to enroll 25% of patients by Q2 2026 and e...
Aclarion announced that Northwestern Medicine and Scripps Health have enrolled their first patients in the CLARITY pivotal trial, bringing the total to four sites with patient enrollments. Seven clinical sites have completed regulatory requirements and are ready to enroll. The company expects initial data readout in Q3 2026 after the first cohort...
Aclarion, a healthcare technology company, was named a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Hub Foundation Awards. The company's Nociscan solution helps physicians identify chronic low back pain sources using MR spectroscopy and AI algorithms.
